How frequently have myelodysplastic syndrome or acute myeloid leukaemia been reported in solid tumour patients receiving Talzenna in clinical studies?

Overall, myelodysplastic syndrome or acute myeloid leukaemia (MDS/AML) has been reported in fewer than 1% of solid tumour patients treated with Talzenna (talazoparib) in clinical studies.